|
Shareprice information |
|
Subscription service |
Financial reports
Latest interim report
27/08/2020 BioInvent Interim Report 1 January – 30 June, 2020
Download PDF (500KB)
Annual Report 2019
Download PDF (9MB)
Press releases:
Presentations
| Webcast | Link |
| Interview with the CEO, Redeye, September 1, 2020 | Click here |
| Presentation of BioInvent's second quarter report 2020, Sweden, August 27, 2020 | Click here |
| Key Opinion Leader call with Prof. Alexander Eggermont, July 21, 2020 | Click here |
| Interview with the CEO, Redeye, April 15, 2020 |
Click here |
| Fight Cancer Seminar Redeye, Stockholm, Sweden, March 10, 2020 |
Click here |
| Presentation of BioInvent's fourth quarter report 2019, Sweden, February 27, 2020 | Click here |
| Interview with Martin Welschof, CEO, Redeye, Lund, Sweden, December 18, 2019 | Click here |
| Redeye Life Science Day 2019, Stockholm, Sweden, November 19, 2019 | Click here |
| Oncology Forum 2019, Stockholm, Sweden, October 7, 2019 | Click here |
| H.C. Wainwright 21st Annual Global Investment Conference, New York, USA, September 9, 2019 | Click here |
| Interview with Martin Welschof, CEO, Pareto TV, Stockholm, Sverige, September 5, 2019 | Click here |
| Presentation of BioInvent's Interim Report Q2-2019, Sweden, August 22, 2019 | Click here |
| Redeye Pre-ASCO Seminar, Stockholm, Sweden, May 28, 2019 | Click here |
| Interview with Martin Welschof, CEO, Pareto TV, Oslo, April 1, 2019 | Click here |
| Interview with Martin Welschof, CEO, Redeye, Stockholm, April 1, 2019 | Click here |
| Fight Cancer Seminar Redeye, Stockholm, Sweden, Januari 22, 2019. | Click here |
| Capital Market Day, Stockholm, Sweden, December 10, 2018. | Click here |
| BioInvent's KOL event, New York, USA, November 6, 2018 | Click here |
| Interview with Björn Frendéus, acting CEO, Dagens Industri, Lund, 24 July, 2018 (Swedish) | Click here |
| Title | Download |
| Audiocast with teleconference Q2 2020, Sweden, August 27, 2020 | Download pdf (0.57 Mb) |
| Key Opinion Leader Call With Prof. Alexander Eggermont, July 21, 2020 | Download pdf (2.61 Mb) |
| Poster Presentation AACR 2020, BT 001, June 22 24, 2020 | Download pdf (0.82 Mb) |
| Poster Presentation AACR 2020, Targeting TNFR2, June 22 24, 2020 | Download pdf (2.23 Mb) |
| Company Presentation, May, 2020 | Download pdf (1.7 Mb) |
| Fight Cancer Seminar Redeye, Stockholm, Sweden, March 10, 2020 | Download pdf (0.52 Mb) |
| Bioinvent Audiocast With Teleconference Q4, Sweden, February 27, 2020 | Download pdf (0.87 Mb) |
| Company Presentation At JP Morgan, San Francisco, USA, January 13 16, 2020 | Download pdf (1.71 Mb) |
| Company Presentation At Cord Communication, Stockholm, Sweden, September 25, 2019 | Download pdf (1.6 Mb) |
| Pareto Securities 10th Annual Health Care Conference, Stockholm, Sweden, 5 September, 2019 | Download pdf (2.18 Mb) |
| International Cancer Cluster Showcase, Philapelphia, USA, June 3, 2019 | Download pdf (0.44 Mb) |
| CEO's report at AGM for 2018, Lund, Sweden, April 25, 2019 | Download pdf (1.68 Mb) |
| Fight Cancer Seminar Redeye, Stockholm, Sweden, January 22, 2019. | Download pdf (1.08 Mb) |
| Capital Market Day, Stockholm, Sweden, December 10, 2018. | Download pdf (2.5 Mb) |
| Poster presentation SITC 2018 Antibody armed oncolytic Vaccinia virus, November 9, 2018. | Download pdf (1.24 Mb) |
| Poster presentation SITC 2018 Treg deleting anti CTLA 4 antibody, November 9, 2018. | Download pdf (7.29 Mb) |
| Corporate presentation, October 17,2018 . | Download pdf (2.58 Mb) |
| CEO's report for 2017, Lund, Sverige, april 24, 2018. | Download pdf (2.77 Mb) |
Investor information
Please find information in this section on our financial calendar, analysts who follow BioInvent and out largest owners.
Choose from the links to access the information.
Financial calendar
Analysts
Ownership
Corporate governance
BioInvent applies the Swedish Code of Corporate Governance ("the Code"). In addition to the Code, BioInvent also complies with applicable rules in the Swedish Companies Act, rules and recommendations ensuring from the Company's listing on NASDAQ OMX Stockholm, and good practices on the stock market.
Investor contact
Martin Welschof, CEO • Tel. +46 (0)46-286 85 50
E-mail: martin.welschof@bioinvent.com
Subscription service